2CBecca
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2CBecca, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families.[1][2] It is a cyclized phenethylamine analogue of the serotonergic psychedelic 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydroisoquinoline ring.[1][2] The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 39–71 nM and 267–850 nM, respectively).[1][2][3][4] 2CBecca was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.[2]
 | |
| Clinical data | |
|---|---|
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H18BrNO2 |
| Molar mass | 348.240 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
